Document is current
Any future updates will be listed below
-
Authors
Feils, A. S. https://orcid.org/0000-0002-9349-4534
Erbe, A. K. https://orcid.org/0000-0003-1175-4062
Birstler, J. https://orcid.org/0000-0002-5247-0632
Kim, K. https://orcid.org/0000-0002-6726-003X
Hoch, U.
Currie, S. L.
Nguyen, T.
Yu, D. https://orcid.org/0000-0002-2468-6030
Siefker-Radtke, A. O. https://orcid.org/0000-0002-6328-9599
Tannir, N. https://orcid.org/0000-0001-5559-8060
Tolaney, S. M. https://orcid.org/0000-0002-5940-8671
Diab, A. https://orcid.org/0000-0002-0153-0244
Sondel, P. M. https://orcid.org/0000-0002-0981-8875
-
Funding
Funding for this research was provided by:
Midwest Athletes Against Childhood Cancer
Stand Up To Cancer
St. Baldrick's Foundation
American Association for Cancer Research
University of Wisconsin Carbone Cancer Center
National Institutes of Health (CA014520, CA014520, CA014520, CA014520, CA014520)
Nektar Therapeutics
- License Information
-
More Information
Article History
Received: 21 October 2022
Accepted: 22 January 2023
First Online: 23 February 2023
Declarations
:
: UH, DY, SLC, and TN are, or were, employees of Nektar Therapeutics, the sponsor of the clinical trial.
: The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by independent ethics committees and the institutional review board at each participating site.
: Written informed consent was obtained from all patients who participated in this study.
